Myeloma: Research
(asked on 18th August 2021) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what research his Department (a) commissioned and (b) evaluated on myeloma in 2018-19; at what cost to the public purse; and what estimate he has made of the cost to the public purse of research on myeloma in each of the next three financial years.
The Department invests in health research through the National Institute for Health Research (NIHR). The following table shows research commissioned by the NIHR into myeloma cancer in 2018-19.
Award title | Total award budget |
Improving the monitoring and treatment of multiple myeloma patients by comparing cellular and serological markers of minimal residual disease | £211,519 |
A research evaluation into myeloma cancer in 2018-19 is not available in the format requested and could only be obtained at disproportionate cost. The following table shows estimated costs for research projects into myeloma in 2021/22 and 2022/23.
Year | 2021/22 | 2022/23 |
Total expenditure | £251,547 | £89,254 |
The estimates for 2023/24 onwards are not currently available as forecast spend is based on payments for contracted project awards. We expect to receive fundable applications within the next two years. The NIHR welcomes funding applications for research into any aspect of human health, including myeloma. As with other Government funders of health research, the NIHR do not allocate funding for specific disease areas.